Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

Lead Sponsor:

University College, London

Collaborating Sponsors:

Medical Research Council

National Institute for Health Research, United Kingdom

Conditions:

Secondary Progressive Multiple Sclerosis

Eligibility:

All Genders

25-65 years

Phase:

PHASE2

Brief Summary

Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects approximately 100,000 people in the UK. Many patients with MS experience two phases of disease; early MS (also ...

Detailed Description

MS-SMART will test the efficacy and mechanism of action of three repurposed drugs (fluoxetine, riluzole and amiloride). All three drugs are in human use and have a good safety record. Critically for t...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of SPMS. Steady progression rather than relapse must be the major cause of increasing disability in the preceding 2 years. Evidence of progression, either an increase of at least one point in EDSS or clinical documentation of increasing disability in patient notes
  • Expanded Disability Status Scale (EDSS) 4.0-6.5
  • Aged 25 to 65 inclusive
  • Women and men with partners of childbearing potential must be using an appropriate method of contraception to avoid any unlikely teratogenic effects of the 3 drugs from time of consent, to 6 weeks after treatment inclusive
  • Women must have a negative pregnancy test within 7 days prior to the baseline visit unless not of child bearing potential (e.g. have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy or they are postmenopausal)
  • Willing and able to comply with the trial protocol (e.g. can tolerate MRI and fulfils the requirements for MRI, e.g. not fitted with pacemakers or permanent hearing aids), ability to understand and complete questionnaires
  • Written informed consent provided

Exclusion

  • Pregnancy or breast feeding patients
  • Baseline MRI scan not of adequate quality for analysis (e.g. too much movement artefact)
  • Significant organ co-morbidity (e.g. malignancy or renal or hepatic failure)
  • Relapse within 3 months of baseline visit
  • Patients who have been treated with iv or oral steroids for an MS relapse/progression within 3 months of baseline visit (these patients can undergo future screening visits once the 3 month window has expired), patients on steroids for another medical condition may enter as long as the steroid prescription is not for multiple sclerosis (relapse/ progression).
  • Use of Simvastatin at 80mg dose within 3 months of baseline visit (lower doses of Simvastatin and other statins are permissible)
  • Commencement of fampridine within 6 months of baseline visit
  • Use of immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine) or disease modifying treatments (β-interferons, glatiramer) within 6 months of baseline visit
  • Use of fingolimod/fumarate/teriflunomide/laquinomod/or other experimental disease modifying treatment (including research of an investigational medicinal product) within 12 months of baseline visit
  • Use of mitoxantrone/ natalizumab/ alemtuzumab/ daclizumab if treated within 12 months of baseline visit
  • Primary progressive MS
  • Relapsing-remitting MS
  • Known hypersensitivity to the active substances and their excipients to any of the active drugs for this trial
  • Use of: lithium, chlorpropamide, triamterene and spironolactone within 6 months of the baseline visit
  • Current use of potassium supplements
  • Current use of tamoxifen
  • Current use of herbal treatments containing St. John's Wort
  • Significant signs of depression
  • Use of an SSRI within 6 months of the baseline visit
  • Use of monoamine oxidase inhibitors, phenytoin, L-tryptophan) and/or neuroleptic drugs within 6 months of the baseline visit
  • A Beck Depression Index score of 19 or higher
  • Bipolar disorder
  • Receiving or previously received Electro-Convulsive Therapy
  • Epilepsy/seizures
  • Glaucoma
  • Patients with a history of bleeding disorders or currently on anticoagulants Routine screening blood values (LFT) \>/ 3 x upper limit of normal (ULN) of site reference ranges (ALT/AST, bilirubin,ˠGT) Potassium \<2.8mmol/l or \>5.5mmol/l
  • Sodium \<125mmol/l
  • Creatinine \>130μmol/l
  • WBCs \<3 x 109/l
  • Lymphocytes \<0.8 x 109/l
  • Neutrophil count \<1.0 x 109 /l
  • Platelet count \<90 x 109 /l
  • Haemoglobin \<80g/l

Key Trial Info

Start Date :

December 18 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 4 2018

Estimated Enrollment :

445 Patients enrolled

Trial Details

Trial ID

NCT01910259

Start Date

December 18 2014

End Date

July 4 2018

Last Update

March 26 2020

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh

Edinburgh, United Kingdom, EH16 4SA

2

Gartnavel Royal Hospital, 1055 Great Western Road

Glasgow, United Kingdom, G12 OXH

3

Brighton and Sussex University Hospitals

Haywards Heath, United Kingdom, RH16 4EX

4

St James's University Hospital

Leeds, United Kingdom, LS9 7TF